Genetics of haemochromatosis

Lancet

Volumn 360, Issue 9346, 2002, Pages 1673-1681

  Bomford, Adrian ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFERRIN RECEPTOR;

ARTHRALGIA; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; FERROPORTIN1 GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENETICS; HEMOCHROMATOSIS; HFE GENE; HOMEOSTASIS; HOMOZYGOTE; HUMAN; IRON ABSORPTION; IRON INTAKE; IRON METABOLISM; LETHARGY; MTP1 GENE; PHENOTYPE; PRIORITY JOURNAL; REG1 GENE; REVIEW; TFR2 GENE;

EID: 0037164344     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11607-2     Document Type: Review

References (145)

1. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet. 13:1996;399-408.
2. Roetto A., Totaro A., Cazzola M., et al. Juvenile hemochromtosis locus maps to chromosome 1q. Am J Hun Genet. 64:1999;1388-1393.
3. Camaschella C., Roetto A., Cali A., et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 25:2000;14-15.
4. Roetto A., Totaro A., Piperno A., et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood. 97:2001;2555-2560.
5. Mattman A., Huntsman D., Lockitch G., et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 Mutation. Blood. 100:2002;1075-1077.
6. Njajou O.T., Vaessen N., Joosse M., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 28:2001;213-214.
7. Montosi G., Donovan A., Totaro A., et al. Autosomal dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 108:2001;619-623.
8. Devalia V., Carter K., Walker A.P., et al. Autosomal dominant reticuloendothelial iron overload associated with a three base pair deletion in the Ferroportin 1 gene (SLC11A3). Blood. 100:2002;695-697.
9. Wallace D.F., Pederson P., Dixon J.L., et al. Novel mutation in ferroportin 1 is associated with autosomal dominant hemochromatosis. Blood. 100:2002;692-694.
10. Kato J., Fujikawa K., Kanda M., et al. A Mutation in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet. 69:2001;191-217.
11. Simon M., Alexandre J.L., Fauchet R., Genetet B., Bourel M. The genetics of haemochromatosis. Prog Med Genet. 4:1980;135-168.
12. Donovan A., Brownlie A., Zhou H., et al. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature. 403:2000;776-781.
13. McKie A.T., Marciani P., Rolfs A., et al. A novel duodenal iron-regulated transporter IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 5:2000;299-309.
14. Abboud S., Haile D.J. A novel mammalian iron regulated protein involved in iron transport. J Biol Chem. 275:2000;19906-19912.
15. Eason R.J., Adams P.C., Aston C.E., Searle J. Familial iron overload with possible autosomal dominant inheritance. Aust N Z J Med. 20:1990;226-230.
16. Cassanelli S. Pignatti, Montosi G, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE]) gene mutations in the healthy adult population in Italy. J Hepatol 2001; 34: 523-28.
17. Piperno A., Sampietro M., Pietrangelo A., et al. Heterogeneity of haemochromatosis in Italy. Gastroenterology. 114:1998;996-1002.
18. Bacon B.R., Powell L.W., Adams P.C., Kresina T.F., Hoofnagle J.H. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology. 116:1999;193-207.
19. Lebron J.A., Bennet M.J., Vaughn D.E., et al. Crystal structure of the hemochromatosis protein HFE and characterisation of its interaction with transferrin receptor. Cell. 93:1998;111-123.
20. Bennet M.J., Lebron J.A., Bjorkman P.J. Crystal structure of the haemochromatosis protein HFE complexed with transferrin receptor. Nature. 403:2000;46-53.
21. Kawabata H., Yang R., Hirama T., et al. Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J Biol Chem. 274:1999;20826-20832.
22. Adams P., Brissot P., Powell L.W. International Consensus Conference on Haemochromatosis, 2: expert document. J Hepatol. 33:2000;485-504.
23. Bacon B.R. Hemochromatosis: diagnosis and management. Gastroenterology. 120:2001;718-725.
24. Tavill A.S. Diagnosis and Management of hemochromatosis. Hepatology. 33:2001;1321-1328.
25. Bothwell T.H., McPhail A.P. Hereditary haemochromatosis: etiologic, pathologic and clinical aspects. Semin Hematol. 35:1998;55-71.
26. Neiderau C., Fisher R., Purschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 110:1996;1107-1119.
27. McCullen M.A., Crawford D.H., Hickman P.E. Screening for hemochromatosis. Clin Chim Acta. 315:2002;169-186.
28. McDonnell S.M., Preston B.L., Jewell S.A., et al. A Survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med. 106:1999;619-624.
29. Houglum K., Ramm G.A., Crawford D.H.G., Witztum J.L., Powell L.W., Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor β1 in genetic hemochromatosis. Hepatology. 26:1997;605-610.
30. Grootveld M., Bell J.D., Halliwell B., Aruomia O.I., Bomford A., Sadler P.J. Non-transferrin bound iron in plasma or serum from patients with idiopathic haemochromatosis: characterisation by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 264:1989;4417-4422.
31. Bacon B.R., Britton R.S. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology. 11:1990;127-137.
32. Simon M., Bourel M., Fauchet R., Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut. 17:1976;332-334.
33. Jazwinska E.C., Cullen L.M., Busfield M., et al. Haemochromatosis and HLA-H. Nat Genet. 14:1996;249-251.
34. Jouanolle A.M., Gandon G., Jezequel P., et al. Haemochromatosis and HLA-H. Nat Genet. 14:1996;251-252.
35. Ban A. The UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut. 44:1997;841-844.
36. Ryan E., O'Keane C., Crowe J. Haemochromatosis in Ireland and HFE. Blood Cells Mol Dis. 24:1998;428-432.
37. Nielsen P., Carpinteiro S., Fischer R., et al. Prevalence of the C282Y and H63D mutations in the HFE gene in pateints with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol. 103:1998;842-845.
38. Datz C., Lalloz M.R., Vogel W., et al. Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. J Hepatol. 27:1997;773-779.
39. Borot N., Roth M.P., Malfroy L., et al. Mutations in the MHC class I-like candidate gene for haemochromatosis in French patients. Immunogenetics. 45:1997;320-324.
40. Rochette J., Pointon J., Fisher C.A., et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet. 64:1999;1056-1062.
41. Cullen L.M., Gao X., Easteal S., Jazwinska E.C. The hemochromatosis 845G→A and 187C→G mutations: prevalence in non-Caucasian populations. Am J Hum Genet. 62:1998;1403-1407.
42. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., Robson K.J. Global prevalence of putative haemochromatosis mutations. J Med Genet. 34:1997;275-278.
43. Hanson E.H., Imperatore G., Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemiol. 154:2001;193-206.
44. Steinberg K.K., Cogswell M.E., Chang J.C., et al. Prevalence of C282Y and H63D mutations in the hemochromotosis (HFE) gene in the United States. JAMA. 285:2001;2216-2222.
45. Burt M.J., George P.M., Upton J.D., et al. The significance of the haemochromatosis gene mutations in the general population: implications for screening. Gut. 43:1998;830-836.
46. Whitfield J.B., Cullen L.M., Jazwinska E.C., et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet. 66:2000;1246-1258.
47. Lucotte G. Frequency analysis and allele map in favour of the Celtic origin of the C282Y mutation of hemochromatosis. Blood Cell Mol Dis. 27:2001;549-556.
48. Jezequel P., Bargain M., Lellouche F., Geffroy F., Dorval I. Allele frequencies of hereditary hemochromatosis gene mutations in a local population of west Brittany. Hum Genet. 102:1998;332-333.
49. Jackson H.A., Carter K., Darke C., et al. HFE mutations, iron deficiency and overload in 10500 blood donors. Br J Haematol. 114:2001;474-484.
50. Andrikovics H., Kalmar L., Bors A., et al. Genotype screening for hereditary hemochromatosis among voluntary blood donors in Hungary. Blood Cell Mol Dis. 27:2001;334-341.
51. Pointon J.J., Wallace D., Merryweather-Clarke A.T., et al. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test. 4:2000;151-161.
52. Mura C., Raguenes O., Ferec C. HFE mutation analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of haemochromatosis. Blood. 93:1999;2502-2505.
53. Wallace D.F., Walker A.P., Pietrangelo A., et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol. 36:2002;474-479.
54. Crawford D.H.G., Jazwinska E.C., Cullen L.M., Powell L.W. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology. 114:1998;1003-1008.
55. Adams P.C., Kertesz A.E., McLaren C.E., et al. Population screening for haemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. 31:2000;1160-1164.
56. Hickman P.E., Hourigan L.F., Powell L.W., et al. Automated measurement of unsaturated iron binding capacity is an effective screen for C282Y homozygous haemochromatosis. Gut. 46:2000;405-409.
57. Asberg A., Hveem K., Thorstensen K., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 36:2001;1108-1115.
58. Bhavnani M., Lloyd D., Bhattacharyya J., et al. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. Gut. 46:2000;707-710.
59. Merryweather-Clarke A.T., Worwood M., Parkinson L., et al. The effects of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol. 101:1998;369-373.
60. Willis G., Wimperis J.Z., Lonsdale R., et al. Incidence of liver disease in people with HFE mutations. Gut. 46:2000;401-404.
61. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet. 359:2002;211-218.
62. Olynyk J.K., Cullen D.J., Aquilia S., et al. A population-based study of the clinical expression of the haemochromatosis gene. N Engl J Med. 341:1999;718-724.
63. Brissot P., Moirand R., Jouanolle A.M., et al. A genotypic study of 217 unrelated probands diagnosed as "genetic haemochromatosis" on "classical" phenotypic criteria. J Hepatol. 30:1999;588-593.
64. Gochee P.A., Powell L.W., Cullen D.J., et al. A population-based study of the biochemical expression of the H63D haemochromatosis mutation. Gastroenterology. 122:2002;646-651.
65. Aguilar-Martinez P., Bismuth M., Picot M.C., et al. Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? Gut. 48:2001;836-842.
66. Bulaj Z.J., Griffen L.M., Jorde L.B., Edwards C.Q., Kushner J.P. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 335:1996;1799-1805.
67. Basset M.L., Halliday J.W., Powell L.W. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 6:1986;24-29.
68. Fletcher L.M., Dixon J.L., Purdie D.M., Powell L.W., Crawford D.H.G. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 122:2002;281-289.
69. Levy J.E., Montross L.K., Andrews N.C. Genes that modfiy the haemochromatosis phenotype in mice. J Clin Invest. 105:2000;1209-1216.
70. Fleming R.E., Holden C.C., Tomatsu S., et al. Mouse strain differences determine severity of iron accumulation in HFE knockout model of hereditary hemochromatosis. Proc Natl Acad Sci USA. 98:2001;2707-2711.
71. Sproule T.J., Jazwinska E.C., Britton R.S., et al. Naturally variant autosomal and sex-linked loci determine the severity of iron overload in β2-microglobulin -deficient mice. Proc Natl Acad Sci USA. 98:2001;5170-5174.
72. McKie A.T., Barrow D., Latunde-Dada G., et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 291:2001;1755-1759.
73. Le Gac G., Mura C., Raguenes O., et al. Nramp2 analysis in hemochromatosis probands. Blood Cells Mol Dis. 26:2000;312-319.
74. Lee P.L., Gelbart T., West C., Halloran C., Felitti V., Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis. 27:2001;783-802.
75. Sachot S., Moirand R., Jouanolle A.-M., et al. Low penetrant haemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region. Blood Cells Mol Dis. 27:2001;518-529.
76. Walker A.P., Wallace D.F., Partridge J., Bomford A.B., Dooley J.S. Atypical haemochromatosis: phenotypic spectrum and β2-microglobulin candidate gene analysis. J Med Genet. 36:1999;537-541.
77. Lee P.L., Ho H.J., Olson R., Beutler E. The effect of transferrin polymorphisms on iron metabolism. Blood Cells Mol Dis. 25:1999;374-379.
78. Lee P.L., Halloran C., West C., Beutler E. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol Dis. 27:2001;285-289.
79. van Vlierberghe H., Langlois M., Delanghe J., et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic pateints. J Hepatol. 35:2001;707-711.
80. Crawford D.H.G., Powell L.W., Leggett B.A., et al. Evidence that the ancestral haplotype in Australian hemochromotosis patients may be associated with a common mutation in the gene. Am J Hum Genet. 57:1995;362-367.
81. Piperno A., Arosio C., Fargion S., et al. The ancestral haemochromatosis haplotype is associated with a severe phenotype in Italian patients. Hepatology. 24:1996;43-46.
82. Pratiwi R., Fletcher L.M., Pyper W.R., et al. Linkage disequilibrium analysis in Australian hemochromatosis patients indicates bipartite association with clinical expression. J Hepatol. 31:1999;39-46.
83. Fargion S., Valenti L., Dongiovanni P., et al. Tumour necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary haemochromatosis. Blood. 97:2001;3707-3712.
84. Ehrlich R., Lemonnier F.A. HFE: a novel nonclassical class I molecule that is involved in iron metabolism. Immunity. 13:2000;585-588.
85. Aisen P., Enns C., Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 33:2001;940-959.
86. Waheed A., Parkkila S., Saarnio J., et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci USA. 96:1999;1579-1584.
87. Parkkila S., Waheed A., Britton R.S., et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA. 94:1997;13198-13202.
88. Olsson L., Goldstein A., Stagsted J. Regulation of receptor internalisation by the major histocompatibility complex class I molecule. Proc Natl Acad Sci USA. 91:1994;9086-9090.
89. Waheed A., Parkkila S., Zhou X.Y., et al. Hereditary haemochromatosis: effects of the C282Y and H63D mutations on association with b2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7cells. Proc Natl Acad Sci USA. 94:1997;12384-12389.
90. Ramalingam T.S., West A.P., Lebron J.A., et al. Binding to the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasis. Nat Cell Biol. 2:2000;953-957.
91. Riedel H.D., Muckenthaler M.U., Gehrke S.G., et al. HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells. Blood. 94:1999;3915-3921.
92. Roy C.N., Penny D.M., Feder J.N., Enns C.A. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem. 274:1999;9022-9028.
93. Corsi B., Levi S., Cozzi A., et al. Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron deficient phenotype. FEBS Lett. 460:1999;149-152.
94. Feeney G., Worwood M. The effects of wild-type and mutant HFE expression upon cellular iron uptake in transfected human embryonic kidney cells. Biochim Biophys Acta. 1538:2001;242-251.
95. Salter-Cid L., Brunmark A., Li Y., et al. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci. 96:1999;5434-5439.
96. Waheed A., Grubb J.H., Zhou X.Y., et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci. 99:2002;3117-3122.
97. Philpott C.C. Molecular aspects of iron absorption: insights into the role of HFE in hemochromatosis. Hepatology. 35:2002;993-1001.
98. Montosi G., Paglia P., Garuti C., et al. Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood. 96:2000;1125-1129.
99. Bastin J.M., Jone M., O'Callaghan C.A., et al. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary hemochromatosis. Br J Haem. 103:1998;931-941.
100. Frazer D.M., Vulpe C.D., McKie A.T., et al. Cloning and gastrointestinal expression of rat hephaestin: relationship to other iron transport proteins. Am J Physiol. 281:2001;G931-939.
101. Parkkila S., Waheed A., Britton R.S., et al. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis reveals a unique pattern of expression in the gastrointestinal tract. Proc Natl Acad Sci. 94:1997;2534-2539.
102. Byrnes V., Ryan E., O'Keane C.O., Crowe J. Immunohistochemistry of the HFE protein in patients with hereditary hemochromatosis, iron deficiency anaemia and normal controls. Blood Cell Mol Dis. 26:2000;2-8.
103. Zuccon L., Corsi B., Levi S., et al. Immunohistochemistry of HFE in the duodenum of C282Y homozygotes with antisera for recombinant HFE protein. Haematologica. 85:2000;346-351.
104. Gunshin H., Mackenzie B., Berger U.V., et al. Cloning and characterisation of a mammalian proton-coupled metal-ion transporter. Nature. 388:1997;482-488.
105. Vulpe C.D., Kuo Y.M., Murphy T.L., et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet. 21:1999;195-199.
106. Zoller H., Koch R., Theurl I., et al. Expression of the duodenal iron transporters divalent metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology. 120:2001;1412-1419.
107. Rolfs A., Bonkovsky H.L., Kohlroser J.G., et al. Intestinal expression of genes involved in iron absorption in humans. Am J Physiol Gastrointest Liver Physiol. 282:2002;G598-607.
108. Fleming R.E., Migas M.C., Zhou X.Y., et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Proc Natl Acad Sci. 96:1999;3143-3148.
109. Griffiths W.J.H., Sly W.S., Cox T.M. Intestinal iron uptake determined by divalent metal transporter is enhanced in HFE-deficient mice with hemochromatosis. Gastroenterology. 120:2001;1420-1429.
110. Dupic F., Fruchon S., Bensaid M., et al. Inactivation of the hemochromatosis gene differentially regulated duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology. 122:2002;745-751.
111. Williams R., Manenti F., Williams H.S., Pitcher C.S. Iron absorption before during and after venesection therapy. BM J. 2:1966;78-81.
112. Finch C. Regulators of iron balance in humans. Blood. 84:1994;1697-1702.
113. Lynch S.R., Skikne B.S., Cook J.D. Food iron absorption in idiopathic hemochromatosis. Blood. 74:1989;2187-2193.
114. Canonne-Hergaux F., Levy J.E., Flemimg M.D., et al. Expression of the DMTI (NRAMP2/DCT1) iron transporter in mice with genetic iron overload disorders. Blood. 97:2001;1138-1140.
115. Ajioka R.S., Ley J.E., Andrews N.C., Kushner J.P. Regulation of iron absorption in Hfe mutant mice. Blood. 100:2002;1465-1469.
116. Santos M., Clevers H., de Sousa M., Marx J.J.M. Adaptive response of iron absorption to anaemia, increased erythropoeisis, iron deficiency, and iron loading in b2-microglobulin knockout mice. Blood. 91:1998;3059-3065.
117. Lombard M., Chua E., O'Toole P. Regulation of intestinal non-haem iron absorption. Gut. 40:1997;435-439.
118. Gavin M.W., McCarthy D.M., Garry P.J. Evidence that iron stores regulate iron absorption: a setpoint theory. Am J Clin Nutr. 59:1994;1376-1380.
119. Parkkila S., Niemela O., Britton R.S., et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology. 121:2001;1489-1496.
120. Trinder D., Olnyk J.K., Sly W.S., Morgan E.H. Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse. Proc Natl Acad Sci. 99:2002;5622-5626.
121. Whittaker P., Skikne B.S., Covell A.M., Flowers C., Lynch S.R., Cook J.D. Duodenal iron proteins in idiopathic hemochromatosis. J Clin Invest. 83:1989;261-267.
122. Pietrangelo A., Casalgrandi G., Quaglino D., et al. Duodenal ferritin synthesis in genetic hemochromatosis. Gastroenterology. 108:1995;208-217.
123. Lombard M.L., Bomford A.B., Polson R.J., Bellingham A.J., Williams R. Differential expression of transferrin receptor in duodenal mucosa in iron overload: evidence for a site-specific defect in genetic hemochromatosis. Gastroenterology. 98:1990;976-984.
124. Theil E.C., Eisenstein R.S. Combinatorial mRNA regulation: iron regulatory proteins and iso-iron-responsive elements (Iso-IREs). J Biol Chem. 275:2000;40659-40662.
125. Roy C.N., Enns C.A. Iron homeostasis: new tales from the crypt. Blood. 96:2000;4020-4027.
126. West A.P., Bennett M.J., Sellers V.M., et al. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem. 275:2000;38135-38138.
127. Krawczak M., Cooper D.N., Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet. 69:2001;361-370.
128. Powell L.W., Subramaniam V.N., Yapp T.R. Haemochromatosis in the new millennium. J Hepatol. 32:(suppl 1):1999;48-62.
129. Allen K., Williamson R. Screening for haemcohromatosis should be implemented now. BMJ. 320:2000;183.
130. Vineis P., Schulte P., McMichael A.J. Misconceptions about the use of genetic tests in populations. Lancet. 357:2001;709-712.
131. Holtzman N.A., Marteau T.M. Will genetics revolutionize medicine. N Engl J Med. 343:2000;141-144.
132. Burke W., Thomson E., Khoury M.J., et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA. 280:1998;172-178.
133. McDonnell S.M., Hover A., Gloe D., et al. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med. 107:1999;30-37.
134. Cogswell M.E., McDonnell S.M., Khoury M.J., et al. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med. 129:1998;971-979.
135. Yang Q., McDonnell S.M., Khoury M.J., Cono J., Parish R.G. Hemochromatosis-associated mortality in the United States from 1979-1992: an analysis of multiple-cause mortality data. Ann Intern Med. 129:1998;946-953.
136. Willis G., Wimperis J.Z., Smith K.C., Fellows I.W., Jennings B.A. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet. 354:1999;221-222.
137. Witte D.L., Crosby W.H., Edwards C.Q. Practice guideline development taskforce of the College of American Pathologists, hereditary hemochromatosis. Clin Chim Acta. 245:1996;139-200.
138. Adams P.C. Population screening for haemochromatosis. Gut. 46:2000;301-303.
139. Crawford D.H.G., Hickman P. Screening for hemochromatosis. Hepatology. 31:2000;1192-1193.
140. Phatack P.D., Guzman G., Woll J.E., Robinson A., Phelps C.E. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 154:1994;769-776.
141. Edwards C.Q., Kushner J.P. Screening for hemochromatosis. N Engl J Med. 328:1993;1616-1620.
142. Adams P.C., Valberg L.S. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 94:1999;1593-1600.
143. Provencale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am. 12:2002;93-109.
144. Bonn D. Genetic testing and insurance: fears unfounded? Lancet. 355:2000;1526.
145. Adam D. UK changes policy on life insurance. Nature. 414:2001;6.